SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, IL – October 15, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer…